CME 1
Translational Molecular Imaging and Therapy + Oncology & Theranostics Committee
Thursday, October 22, 13:30-15:00

Session Title
Radar on Gynaecological Cancers

Chairperson
Alessandra Alessi (Milan, Italy)

Programme
13:30 - 13:52 Cristina Nanni (Bologna, Italy): PET/CT Guided Response Assessment in Gynaecological Tumours
13:52 - 14:14 Judit Adam (Amsterdam, Netherlands): PET/CT in Radiotherapy Treatment Planning
14:14 - 14:36 Sergi Vidal-Sicart (Barcelona, Spain): Interventional Nuclear Medicine Techniques for Gynaecological Tumours
14:36 - 14:58 Susanne Kossatz (Munich, Germany): New Radiopharmaceuticals for Improved Diagnosis in Gynaecological Tumours - What is the Future?

Educational Objectives
1. To learn the role of functional imaging in the evaluation of response to therapies in gynaecological cancers
2. To understand the value of image guided surgery in gynaecological cancers
3. To explore the future of nuclear imaging in gynaecological cancers

Summary
Gynecologic cancers are a varied group of malignancies with diverse clinical presentations and prognosis. PET with [18F]-FDG is the most commonly used radiopharmaceutical, but translational efforts to introduce new radiopharmaceuticals for gynaecologic indications are ongoing. While accurate diagnosis of a disease provides a valuable first step in its cure, imaging may also impact patient care by providing therapeutic guidance. Hence the presenters will also illustrate if and how gynecological imaging can be used to assess the response to therapies and can, in some cases, even guided surgical resection of a disease.

Key Words
Molecular imaging and new radiotracers, therapy response, image guided treatments, new radiotracers